Sponsors Must Repeat Studies Done by Troubled Indian CROs, FDA Cautions
November 2, 2021
In a rare move, the FDA has informed sponsors that used two Indian CROs with concerning data integrity practices that some studies those firms conducted will need to be repeated.
